Search research articles
Contact Us
Filters
Showing results (61-70 of 129) with videos related to
Page
of 13
Sort By:
JAMA Oncology
|
September 21, 2023
Risk-Directed Ambulatory Thromboprophylaxis in Lung and Gastrointestinal Cancers: The TARGET-TP Randomized Clinical Trial
Marliese Alexander, Sam Harris, Craig Underhill, et al.
The Lancet. Oncology
|
October 28, 2017
Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial
Alice T Shaw, Enriqueta Felip, Todd M Bauer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 30, 2016
Intracranial Efficacy of Crizotinib Versus Chemotherapy in Patients With Advanced ALK-Positive Non-Small-Cell Lung Cancer: Results From PROFILE 1014
Benjamin J Solomon, Federico Cappuzzo, Enriqueta Felip, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
August 4, 2023
Efficacy of Lorlatinib in Treatment-Naive Patients With ALK-Positive Advanced NSCLC in Relation to EML4::ALK Variant Type and ALK With or Without TP53 Mutations
Alessandra Bearz, Jean-François Martini, Jacek Jassem, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
November 25, 2010
Rapid and dramatic radiographic and clinical response to an ALK inhibitor (crizotinib, PF02341066) in an ALK translocation-positive patient with non-small cell lung cancer
Sai-Hong Ignatius Ou, Lyudmila Bazhenova, D Ross Camidge, et al.
JCO Precision Oncology
|
January 7, 2022
Novel RET Fusion <i>RET-SEPTIN9</i> Predicts Response to Selective RET Inhibition With Selpercatinib in Malignant Pheochromocytoma
Angela Mweempwa, Huiling Xu, Joseph H A Vissers, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
June 9, 2023
Early Circulating Tumor DNA Dynamics and Efficacy of Lorlatinib in Patients With Treatment-Naive, Advanced, ALK-Positive NSCLC
Ross A Soo, Jean-François Martini, Anthonie J van der Wekken, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 28, 2015
Clinical Experience With Crizotinib in Patients With Advanced ALK-Rearranged Non-Small-Cell Lung Cancer and Brain Metastases
Daniel B Costa, Alice T Shaw, Sai-Hong I Ou, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 2, 2011
MET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib
Jochen K Lennerz, Eunice L Kwak, Allison Ackerman, et al.
The Lancet. Oncology
|
November 1, 2019
Lorlatinib in advanced ROS1-positive non-small-cell lung cancer: a multicentre, open-label, single-arm, phase 1-2 trial
Alice T Shaw, Benjamin J Solomon, Rita Chiari, et al.
Page
of 13
Search research articles
Search
Showing results (61-70 of 129) with videos related to
Sort By:
Page
of 13
JAMA Oncology
|
September 21, 2023
Risk-Directed Ambulatory Thromboprophylaxis in Lung and Gastrointestinal Cancers: The TARGET-TP Randomized Clinical Trial
Marliese Alexander, Sam Harris, Craig Underhill, et al.
The Lancet. Oncology
|
October 28, 2017
Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial
Alice T Shaw, Enriqueta Felip, Todd M Bauer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 30, 2016
Intracranial Efficacy of Crizotinib Versus Chemotherapy in Patients With Advanced ALK-Positive Non-Small-Cell Lung Cancer: Results From PROFILE 1014
Benjamin J Solomon, Federico Cappuzzo, Enriqueta Felip, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
August 4, 2023
Efficacy of Lorlatinib in Treatment-Naive Patients With ALK-Positive Advanced NSCLC in Relation to EML4::ALK Variant Type and ALK With or Without TP53 Mutations
Alessandra Bearz, Jean-François Martini, Jacek Jassem, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
November 25, 2010
Rapid and dramatic radiographic and clinical response to an ALK inhibitor (crizotinib, PF02341066) in an ALK translocation-positive patient with non-small cell lung cancer
Sai-Hong Ignatius Ou, Lyudmila Bazhenova, D Ross Camidge, et al.
JCO Precision Oncology
|
January 7, 2022
Novel RET Fusion <i>RET-SEPTIN9</i> Predicts Response to Selective RET Inhibition With Selpercatinib in Malignant Pheochromocytoma
Angela Mweempwa, Huiling Xu, Joseph H A Vissers, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
June 9, 2023
Early Circulating Tumor DNA Dynamics and Efficacy of Lorlatinib in Patients With Treatment-Naive, Advanced, ALK-Positive NSCLC
Ross A Soo, Jean-François Martini, Anthonie J van der Wekken, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 28, 2015
Clinical Experience With Crizotinib in Patients With Advanced ALK-Rearranged Non-Small-Cell Lung Cancer and Brain Metastases
Daniel B Costa, Alice T Shaw, Sai-Hong I Ou, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 2, 2011
MET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib
Jochen K Lennerz, Eunice L Kwak, Allison Ackerman, et al.
The Lancet. Oncology
|
November 1, 2019
Lorlatinib in advanced ROS1-positive non-small-cell lung cancer: a multicentre, open-label, single-arm, phase 1-2 trial
Alice T Shaw, Benjamin J Solomon, Rita Chiari, et al.
Page
of 13